23.58 USD
-0.87 (-3.56%)
23.58 USD
0 (0%)
CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, CPRX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
- CPRX had positive earnings in the past year.
- In the past year CPRX had a positive cash flow from operations.
- In the past 5 years CPRX has always been profitable.
- CPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- CPRX has a Return On Assets of 20.69%. This is amongst the best in the industry. CPRX outperforms 97.14% of its industry peers.
- CPRX's Return On Equity of 23.65% is amongst the best of the industry. CPRX outperforms 96.76% of its industry peers.
- CPRX has a Return On Invested Capital of 21.23%. This is amongst the best in the industry. CPRX outperforms 97.90% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 18.07%.
- The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
- CPRX has a Profit Margin of 37.64%. This is amongst the best in the industry. CPRX outperforms 96.76% of its industry peers.
- In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
- With an excellent Operating Margin value of 44.78%, CPRX belongs to the best of the industry, outperforming 99.43% of the companies in the same industry.
- CPRX's Operating Margin has improved in the last couple of years.
- The Gross Margin of CPRX (85.68%) is better than 88.38% of its industry peers.
- CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CPRX is creating value.
- Compared to 1 year ago, CPRX has more shares outstanding
- Compared to 5 years ago, CPRX has more shares outstanding
- There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- CPRX has an Altman-Z score of 16.51. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
- CPRX has a Altman-Z score of 16.51. This is amongst the best in the industry. CPRX outperforms 86.29% of its industry peers.
- CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.51 |
ROIC/WACC2.39
WACC8.88%
2.3 Liquidity
- CPRX has a Current Ratio of 6.62. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of CPRX (6.62) is better than 67.62% of its industry peers.
- CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 6.40, CPRX is doing good in the industry, outperforming 66.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
- CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.76%, which is quite impressive.
- The Earnings Per Share has been growing by 34.29% on average over the past years. This is a very strong growth
- CPRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.56%.
- CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.89% yearly.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
- The Earnings Per Share is expected to grow by 26.80% on average over the next years. This is a very strong growth
- CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.21% yearly.
EPS Next Y24.97%
EPS Next 2Y18.55%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.37%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 13.71, CPRX is valued correctly.
- CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.76% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.21. CPRX is valued slightly cheaper when compared to this.
- With a Price/Forward Earnings ratio of 12.81, CPRX is valued correctly.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.76% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of CPRX to the average of the S&P500 Index (24.26), we can say CPRX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.71 | ||
| Fwd PE | 12.81 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaper than 98.10% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.71% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.35 | ||
| EV/EBITDA | 7.8 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of CPRX may justify a higher PE ratio.
- A more expensive valuation may be justified as CPRX's earnings are expected to grow with 12.53% in the coming years.
PEG (NY)0.55
PEG (5Y)0.4
EPS Next 2Y18.55%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
- No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 24.97% in the next year.